NCT07382778Completed
Efficacy and Safety of Livalozet® in Hypercholesterolemic Patients With and Without Diabetes
A Multi-center, Open-label, Observational Study to Compare and Evaluate the Efficacy and Safety of Livalozet® According to the Presence or Absence of Diabetes Mellitus in Hypercholesterolemia Patients
Source: ClinicalTrials.gov · Last updated 3 Feb 2026
Brief summary (registry, in English)
A Multi-center, Open-label, Observational Study to Compare and Evaluate the Efficacy and Safety of Livalozet® according to the Presence or Absence of Diabetes Mellitus in Hypercholesterolemia Patients
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1538 (actual)
- First submitted
- 27 Jan 2026
- Start date
- 19 Oct 2022
- Primary completion date
- 13 Jun 2025
- Lead sponsor
- JW Pharmaceutical
- Diseases
- Familial hypercholesterolaemia
- NCT number
- NCT07382778
What you commit to
- Study type: Observational
- Participants enrolled: 1538
- From 19 Oct 2022 to the primary completion date, 13 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \- Contraindications to Livalozet®
Who the study is looking for
- Men and women aged ≥19 years
- Diagnosed with hypercholesterolemia
- LDL-C level meets cardiovascular/cerebrovascular risk group classification
- Willing to participate for 12 months
- Provided written informed consent
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Seoul National University Bundang Hospital Coordinator of this site? Confirm its status | Seongnam-si | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.